Search

Your search keyword '"Lampidis T"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Lampidis T" Remove constraint Author: "Lampidis T"
84 results on '"Lampidis T"'

Search Results

2. Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors

10. Accumulation of simple organic cations correlates with differential cytotoxicity in multidrug-resistant and -sensitive human and rodent cells.

15. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells.

16. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells.

17. Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors

23. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer

24. Glucose and mannose analogs inhibit KSHV replication by blocking N-glycosylation and inducing the unfolded protein response.

25. Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

26. Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors.

27. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.

28. Differential expression of Glut 1 mRNA and protein levels correlates with increased sensitivity to the glyco-conjugated nitric oxide donor (2-glu-SNAP) in different tumor cell types.

29. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

30. Procollagen alpha 1 type 1: a potential aide in histopathological grading of glioma.

31. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine.

32. Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs.

33. Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems.

34. Phenotypic diversity in human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues.

35. Multidrug-resistant gene expression in small-cell lung cancer.

36. Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux.

37. Antiproliferative activity of taxol on human tumor and normal breast cells vs. effects on cardiac cells.

38. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.

39. Structural requirements of simple organic cations for recognition by multidrug-resistant cells.

40. Alpha-smooth muscle actin expression in cultured cardiac fibroblasts of newborn rat.

41. Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors.

42. 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.

43. Interferon inhibits cardiac cell function in vitro.

44. Structural and functional effects of adriamycin on cardiac cells in vitro.

45. Effect of verapamil on rhodamine 123 mitochondrial damage in adriamycin resistant cells.

46. Relevance of the chemical charge of rhodamine dyes to multiple drug resistance.

48. Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis.

49. Membrane potential differences between adriamycin-sensitive and -resistant cells as measured by flow cytometry.

50. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.

Catalog

Books, media, physical & digital resources